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for warfarin. Another alternative to warfarin in patients with
AF is the recently-approved direct thrombin inhibitor, 
dabigatran. A potential advantage of apixaban is that it is
reversible, whereas dabigatran has no antidote. The relative
efficacy and safety of apixaban versus dabigatran for stroke
prevention in AF remain to be determined.   
Summary written by: Fred Morady, MD
Extent of and Reasons for Nonuse of Implantable
Cardioverter Defibrillator Devices in Clinical
Practice Among Eligible Patients With Left
Ventricular Systolic Dysfunction
LaPointe NM, Al-Khatib SM, Piccini JP, et al.
Circ Cardiovasc Qual Outcomes 2011;Feb 8:[Epub ahead of print].
Study Question: How often do eligible patients with heart fail-
ure (HF) not receive an implantable cardioverter- 
defibrillator (ICD) for primary prevention of sudden cardiac
death (SCD)? 
Methods: The medical records of 542 patients (median age 64
years) with HF and an ejection fraction (EF) ≤30% were
reviewed to determine if an ICD was implanted within 1 year
of the index HF hospitalization. If not, data on contraindica-
tions (e.g., patient refusal, severe dementia, nonoptimal
medical therapy, limited life expectancy) were collected.
Results: Forty-one percent of the 542 patients did not receive
an ICD. A valid contraindication was identified in the major-
ity of these patients. Among the 542 patients, 13% of those
eligible did not receive an ICD despite absence of a con-
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Arrhythmias
Apixaban in Patients With Atrial Fibrillation
Connolly SJ, Eikelboom J, Joyner C, et al.
N Engl J Med 2011;Feb 10:[Epub ahead of print].
Study Question: Is apixaban superior to aspirin for stroke pre-
vention in atrial fibrillation (AF)?   
Methods: In this double-blind study, 5,599 patients (mean
age 70 years) with AF and ≥1 risk factor for stroke who were
unsuitable candidates for warfarin were randomly assigned to
receive apixaban, 5 mg twice daily (n = 2,808), or aspirin,
81-325 mg/day (n = 2,791). The patients were followed for a
mean of 13 months. The primary outcomes were stroke/sys-
temic embolism and major bleeding.
Results: The incidence of stroke/embolism was significantly
lower in the apixaban (1.6%/year) than the aspirin group
(3.7%/year). The 3.5%/year mortality rate in the apixaban
group did not differ significantly from the 4.4%/year mortality
rate in the aspirin group. The annual incidence of major
bleeding also did not differ significantly between the apixaban
(1.4%) and aspirin (1.2%) groups. First hospitalizations for a
cardiovascular cause were significantly less common with
apixaban (12.6%/year) than aspirin (15.9%).
Conclusions: Compared to aspirin, apixaban reduces the risk
of stroke/embolism by 55% without increasing the risk of
bleeding complications.
Perspective: This study is the first to evaluate the efficacy of
apixaban in patients with AF who are not suitable candidates
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albeit nonspecific, can identify important ablation sites.  
Summary written by: Elizabeth A. Jackson, MD
Congenital Heart Disease
Prenatal Ultrasound Screening of Congenital Heart
Disease in an Unselected Population: A 21-Year
Experience 
Marek J, Tomek V, Škovránek J, Povýšilová V, Šamánek M.
Heart 2011;97:124–130.
Study Question: What is the prevalence of congenital heart dis-
ease and the impact of a national prenatal ultrasound screening
program on outcomes in a discrete patient population?     
Methods: A comprehensive national registry was created,
which enabled confirmation of pre- and post-natal findings
clinically and by post-mortem examination. As part of the
centralized health care system in the Czech Republic, all
pregnant women underwent screening ultrasounds by obste-
tricians trained by pediatric cardiologists. Women with
abnormal screening ultrasounds were referred for formal fetal
cardiac evaluation. Post-natal examination, echocardiogra-
phy, and post-mortem examinations were used to correlate
post-natal findings with fetal ultrasonography.
Results: Of 9,475 fetuses referred for formal fetal echocardio-
grams, 1,604 (16.9%) had congenital heart disease, of which
501 (31.2%) also had extracardiac anomalies. Over the study
period (1986-2006), detection rates were highest for double-
outlet right ventricle and hypoplastic left heart syndrome
(HLHS) at 77.3% and 50.6%, respectively. There was
improvement in detection rates over the course of the study.
For the final years of the study, detection rate for HLHS
was 95.8%, while transposition of the great arteries was diag-
nosed antenatally in 25.6% of fetuses. Termination of
pregnancy occurred in 57.3% of infants found to have con-
genital heart disease.
Conclusions: A centralized health care system and prenatal
registry give detailed data on the prevalence and spectrum of
congenital heart disease.
Perspective: Detection rates improved significantly over the
course of this study, although diagnosis of transposition of
the great arteries remained a challenge, with approximately
three-quarters of fetuses going undetected. Prenatal diagno-
sis of transposition is important in that it allows the child to
be born at a center where there is rapid access to interven-
tions such as balloon atrial septostomy. An extremely high
elective termination rate of 57.3% limits interpretation of the
post-natal results of this study.  
Summary written by: Timothy B. Cotts, MD
1504 Eagle, Cannon
Scanning the Literature
JACC, Vol. 57, No. 14, 2011
April 5, 2011:1503–10
traindication. The lack of ICD use was not associated with
age or gender, but was associated with hospitalization on a
noncardiology service (odds ratio [OR], 3.7) and lack of
health insurance (OR, 3.1).
Conclusions: The true underutilization rate of ICDs for the
primary prevention of SCD is substantially lower than the
proportion of patients with HF who meet the EF criterion
of ≤30%.
Perspective: Prior studies have reported ICD underutilization
rates as high as 30-40%, but were based largely on identifica-
tion of patients with HF or prior MI who had an EF
≤30-35%. In this study, after detailed chart review, the
underutilization rate fell from 41% to only 13%. However,
the study was performed at a single academic center and the
results may not be applicable to general practice.   
Summary written by: Fred Morady, MD
Additional Ablation of Complex Fractionated Atrial
Electrograms (CFAEs) After Pulmonary Vein
Isolation (PVAI) in Patients With Atrial Fibrillation:
A Meta-Analysis
Li W, Bai Years, Zhang H, et al.
Circulation Arrhyth Electrophysiol 2011;Feb 8:[Epub ahead of print].
Study Question: Does ablation of complex fractionated atrial
electrograms (CFAEs) improve the efficacy of radiofrequency
catheter ablation (RFCA) of atrial fibrillation (AF) when
performed after pulmonary vein antrum isolation (PVAI)?   
Methods: This was a meta-analysis of seven studies that com-
pared PVAI (n = 330) to PVAI plus CFAE ablation (n =
332) in 662 patients with AF. The mean follow-up was 12-
19 months. The primary outcome was freedom from AF in
the absence of antiarrhythmic drug therapy after a single
ablation procedure.
Results: Additional RFCA of CFAEs did not improve efficacy
in patients with paroxysmal AF. In patients with persistent
AF, additional RFCA of CFAEs was associated with a signif-
icant relative improvement in efficacy of 35% compared to
PVAI by itself.
Conclusions: Compared to PVAI by itself, the additional
RFCA of CFAEs has incremental value in patients with
persistent AF, but not in patients with paroxysmal AF.
Perspective: CFAEs may be created by several different mech-
anisms, some of which play a role in maintaining AF. In
paroxysmal AF, the pulmonary veins usually are the predomi-
nant source of the triggers and drivers of AF; therefore,
additional ablation of CFAEs is unnecessary, as reflected in
the results of this meta-analysis. In contrast, in persistent AF,
extrapulmonary vein mechanisms are common and CFAEs,
Association of Myocardial Enzyme Elevation and
Survival Following Coronary Artery Bypass Graft
Surgery
Domanski MJ, Mahaffey K, Hasselblad V, et al.
JAMA 2011;305:585–591.
Study Question: What is the relationship between peak post-
coronary artery bypass grafting (CABG) elevation of
biomarkers of myocardial damage and early, intermediate-,
and long-term mortality?  
Methods: Studies (randomized clinical trials or registries) of
patients undergoing CABG surgery, in which postproce-
dural biomarker and mortality data were collected, were
included. A search of the PubMed database was per-
formed in July 2008 using the search terms coronary artery
bypass, troponin, creatine kinase-myocardial band (CK-
MB), and mortality. Once institutional review board
approval for use of these data was obtained, the authors
requested patient-level data from each source. Data were
examined to ensure that cardiac markers had been meas-
ured within 24 hours after CABG surgery, key baseline
covariates, and mortality were available. To examine the
longer-term relationship of the CK-MB and troponin
ratio to mortality, the investigators fitted a Cox propor-
tional hazards model for mortality from 0 to 30 days, 30
days to 1 year, and from 1 to 5 years. 
Results: A total of 18,908 patients from seven studies were
included. Follow-up varied from 3 months to 5 years.
Mortality was found to be a monotonically increasing
function of the CK-MB ratio. The 30-day mortality rates
by categories of CK-MB ratio were 0.63% for 0 to <1,
0.86% for 1 to <2, 0.95% for 2 to <5, 2.09% for 5 to <10,
2.78% for 10 to <20, and 7.06% for 20 to ≥40. The CK-
MB ratio was the strongest independent predictor of death
to 30 days and remained significant even after adjusting
for a wide range of baseline risk factors (χ2 = 143, p <
0.001). This result was strongest at 30 days, but the
adjusted association persisted from 30 days to 1 year (χ2 =
24; p < 0.001) and a trend was present from 1 to 5 years
(χ2 = 2.8; p = 0.10). Similar analyses using troponin as the
marker of necrosis led to the same conclusions (χ2 = 142
for 0-30 days and χ2 = 40 for 30 days to 6 months, both p
< 0.001).  
Conclusions: Among patients who had undergone CABG sur-
gery, elevation of CK-MB or troponin levels within the first
24 hours was independently associated with increased inter-
mediate- and long-term risk of mortality.
Perspective: In this large study, mortality more than dou-
bled at a CK-MB ratio of 4.4, and qualitatively similar
results were seen for troponin elevation. These findings
Cardiovascular Surgery
Impact of Early Surgery on Survival of Patients
With Severe Mitral Regurgitation 
Samad Z, Kaul P, Shaw LK, et al.
Heart 2011;97:221–224. 
Study Question: Is there an association between the timing of
surgery and long-term survival in patients with severe degen-
erative mitral regurgitation (MR)?
Methods: A cohort of 481 patients with severe degenerative
MR between 1995 and 2007, and at least one American
College of Cardiology/American Heart Association
(ACC/AHA) guideline indication for surgery, was identi-
fied from the Duke Cardiovascular Disease Databank.
Patients were grouped into early surgery (≤2 months of pre-
senting with surgical indications) and late surgery (>2
months). An adjusted Cox regression model was constructed
for time to death after 2 months, with a time-dependent
covariate term for late surgery.
Results: A total of 168 patients had early surgery (median
time to surgery, 0.42 months), of whom 153 were followed
up after 2 months; 94 patients had late surgery (median time
to surgery, 8.75 months); and 219 were medically managed.
A total of 127 (76%) of 168 early surgery patients and 84
(89%) of 94 late surgery patients underwent mitral repair (p
= 0.02). Over 5.6-year median follow-up, there were 35
deaths (21%) in the early surgery group, with two occurring
before 2 months, and 20 deaths (21%) in the late group. In
the multivariable model, patients undergoing early surgery
had a lower hazard for death than those who underwent late
surgery (hazard ratio [HR], 0.54). Mitral repair was inde-
pendently associated with survival (HR, 0.45). 
Conclusions: In these patients with severe degenerative MR,
early surgery patients had better survival than late surgery
patients. These data support the current guidelines for early
referral to surgery in patients with severe MR for enlarged left
ventricular dimensions, reduced ejection fraction, and symp-
toms, rather than delaying surgery. Larger randomized trials
are needed to definitively answer the question of optimal tim-
ing of surgery in patients with severe degenerative MR.
Perspective: Data from this retrospective, observational study
support that, once there is an indication for surgical interven-
tion for severe degenerative MR, outcomes might be better if
surgery is not deferred. Inasmuch as chronic MR is an indo-
lent disease, the development an ACC/AHA indication for
intervention heralds decompensation, and complacency should
be discouraged.  
Summary written by: David S. Bach, MD
JACC, Vol. 57, No. 14, 2011
April 5, 2011:1503–10
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require confirmation in large prospective studies, and if
confirmed, may influence the design of future clinical trials
with respect to using cardiac markers as an outcome meas-
ure following CABG surgery. The appropriate threshold
level for choosing an enzyme increase as a predictor of
worse prognosis also needs to be defined in future studies.  
Summary written by: Debabrata Mukherjee, MD
Effect of Timing of Chronic Preoperative Aspirin
Discontinuation on Morbidity and Mortality in
Coronary Artery Bypass Surgery 
Jacob M, Smedira N, Blackstone E, Williams S, Cho L.
Circulation 2011;123:577–583.
Study Question: Does timing of aspirin discontinuation prior
to coronary artery bypass grafting (CABG) affect out-
comes? 
Methods: At the Cleveland Clinic, 2,298 chronic aspirin
(ASA) users discontinued ASA 6 or more days before
CABG (early discontinuation), and 1,845 took ASA within
5 days of the surgery (late use). Propensity score analysis to
better match groups based on 31 variables resulted in 1,519
well-matched pairs of patients (73%).
Results: There was no significant difference between those
with early discontinuation and late ASA use with regard to
the composite outcome of in-hospital mortality, myocardial
infarction, and stroke (1.7% vs. 1.8%, p = 0.80). Late use
was associated with more intraoperative (23% vs. 20%, p =
0.03) and postoperative (30% vs. 26%, p = 0.009) transfu-
sions, but a similar number of reoperations for bleeding
(3.4% vs. 2.4%, p = 0.10).
Conclusions: Among patients undergoing CABG, late dis-
continuation of ASA resulted in no difference in
postoperative cardiovascular outcomes; however, there was
an increased transfusion requirement.
Perspective: Guidelines regarding discontinuation of ASA
prior to CABG vary widely. Considering variability in the
response to ASA, the two groups in this study may not be
that different; however, increased bleeding was noted in the
group of patients with late ASA discontinuation without
evidence of benefit. It would be interesting to compare a
group that continues ASA up to the day of CABG, as bene-
fits may outweigh risks in this setting. A randomized,
controlled trial is needed to address this important issue.  
Summary written by: Daniel T. Eitzman, MD
General Cardiology
Identification of ADAMTS7 as a Novel Locus for
Coronary Atherosclerosis and Association of ABO
With Myocardial Infarction in the Presence of
Coronary Atherosclerosis: Two Genome-Wide
Association Studies 
Reilly MP, Li M, He J, et al.
Lancet 2011;377:383–392.
Study Question: Are there distinct gene variants associated
with atherosclerosis and myocardial infarction (MI)? 
Methods: Genome-wide association studies (GWAS) with
coronary angiographic phenotyping were performed in par-
ticipants of European ancestry. To identify loci that
predispose to angiographic coronary artery disease (CAD),
individuals who had this disorder (n = 12,393) were com-
pared to those who did not (controls, n = 7,383). To
identify loci that predispose to MI, patients who had angio-
graphic CAD and MI (n = 5,783) were compared to those
who had angiographic CAD, but no MI (n = 3,644).
Results: In the comparison of patients with angiographic
CAD versus controls, a novel locus, ADAMTS7 (p = 4.98 ×
10–13), was identified. In the comparison of patients with
angiographic CAD who had MI versus those with angio-
graphic CAD but no MI, a novel association at the ABO
locus (p = 7.62 × 10–9) was identified. The ABO association
was attributable to the enzyme that encodes the ABO blood
group O phenotype previously proposed to protect against
MI.
Conclusions: Specific genetic predispositions promote the
development of coronary atherosclerosis, whereas others lead
to MI in the presence of coronary atherosclerosis. The rela-
tion to specific CAD phenotypes might modify how novel
loci are applied in personalized risk assessment and used in
the development of novel therapies for CAD.
Perspective: It is not surprising that different genes affect
different stages of atherothrombotic disease. To distinguish
these relationships, it is important to improve vascular phe-
notyping strategies in GWAS, as was done in this study
using coronary angiography. As a result, not only were
novel genetic associations with atherosclerosis and MI dis-
covered in this study, but it provided some insight into the
potential mechanisms by which these genes may promote
vascular disease.  
Summary written by: Daniel T. Eitzman, MD
1506 Eagle, Cannon
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candesartan was associated with a nonsignificant increased
risk for adverse outcomes. Future trials may help to clarify
whether this finding is generalizable to all patients and all
antihypertensives. Until additional data are available, there
does not appear to be any role for routine blood pressure
lowering treatment in the acute phase of stroke.  
Summary written by: Elizabeth A. Jackson, MD
Quantitative Troponin and Death, Cardiogenic
Shock, Cardiac Arrest and New Heart Failure in
Patients With Non-ST-Segment Elevation Acute
Coronary Syndromes (NSTE ACS): Insights From
the Global Registry of Acute Coronary Events
Jolly SS, Shenkman H, Brieger D, et al., on behalf of the GRACE
Investigators.
Heart 2011;97:197–202.
Study Question: What is the implication of the absolute level of
troponin elevation in patients with non–ST-segment elevation
acute coronary syndromes (NSTE-ACS)?  
Methods: The authors assessed the impact of the absolute
troponin level in 16,318 patients with NSTE-ACS enrolled
in the Global Registry of Acute Coronary Events
(GRACE). The maximum 24-hour troponin value as a
multiple of the local laboratory upper limit of normal
(ULN) was used to divide the population into five groups,
and association with in-hospital death and other outcomes
was compared.
Results: An increase in rate of in-hospital death (0.8, 2.2, 3.0,
5.3, and 14.0%; p < 0.001), cardiogenic shock (0.5, 1.4, 2.0,
4.4, and 12.7%; p < 0.001), new-onset congestive heart failure
(2.5, 5.1, 7.4, 11.6, and 15.8%; p < 0.001), and cardiac
arrest/sustained ventricular tachycardia/ventricular fibrillation
(VT/VF) (1.0, 2.4, 3.4, 5.9, and 13.4%; p < 0.001) was seen
with every 10-fold increase in troponin level. Troponin ratio
was a significant predictor of cardiac arrest, sustained VT, or
VF; cardiogenic shock; and new-onset heart failure. Troponin
elevation was associated with both early mortality (p < 0.001
for days 0-14) and longer-term (days 15-180) mortality (p =
0.001. 
Conclusions: A greater degree of troponin elevation is associ-
ated with worse outcome in patients with NSTE-ACS.
Perspective: This elegant study demonstrates a strong associa-
tion between degree of troponin elevation and adverse events
in patients with NSTE-ACS. The rate of adverse events was
strikingly high in patients who had troponin elevation >100 x
ULN, although an increase in adverse events was also seen in
patients with lesser troponin elevation. Troponin level is rou-
tinely ascertained in patients with ACS, is readily available,
The Angiotensin-Receptor Blocker Candesartan for
Treatment of Acute Stroke (SCAST): A
Randomised, Placebo-Controlled, Double-Blind
Trial 
Sandset EC, Bath PM, Boysen G, et al.
Lancet 2011;377:741–750. 
Study Question: What is the effect of careful blood pressure
lowering treatment with the angiotensin-receptor blocker
candesartan in patients with acute stroke and raised blood
pressure? 
Methods: Participants in this randomized, placebo-controlled,
double-blind trial were recruited from 146 centers in nine
north European countries. Patients older than 18 years with
acute stroke and systolic blood pressure of 140 mm Hg or
higher were included within 30 hours of symptom onset.
Patients were randomly allocated to candesartan or placebo
(1:1) for 7 days, with doses increasing from 4 mg on day 1
to 16 mg on days 3-7. There were two co-primary effect
variables: the composite endpoint of vascular death, myocar-
dial infarction, or stroke during the first 6 months; and
functional outcome at 6 months, as measured by the modi-
fied Rankin Scale.
Results: A total of 2,029 patients were randomly allocated to
treatment groups (1,017 candesartan, 1,012 placebo), and
data for status at 6 months were available for 2,004 patients
(99%; 1,000 candesartan, 1,004 placebo). During the 7-day
treatment period, blood pressures were significantly lower in
patients allocated candesartan than in those on placebo
(mean 147/82 mm Hg in the candesartan group on day 7 vs.
152/84 mm Hg in the placebo group; p < 0.0001). During 6
months’ follow-up, the risk of the composite vascular end-
point did not differ between treatment groups (candesartan,
120 events vs. placebo, 111 events; p = 0.52). Analysis of
functional outcome suggested a higher risk of poor outcome
in the candesartan group (p = 0.048 [not significant at p ≤
0.025 level]). The observed effects were similar for all pre-
specified secondary endpoints and outcomes, and there was
no evidence of a differential effect in any of the prespecified
subgroups. During follow-up, nine patients on candesartan
and five on placebo had symptomatic hypotension, and renal
failure was reported for 18 patients taking candesartan and
13 allocated placebo. 
Conclusions: Careful blood pressure lowering treatment with
candesartan is not beneficial in patients with acute stroke and
raised blood pressure.
Perspective: This study did not demonstrate any evidence of a
beneficial effect of careful blood pressure lowering treatment
with an angiotensin-receptor blocker in patients with acute
stroke and elevated blood pressure. Instead, treatment with
JACC,  Vol. 57, No. 14, 2011
April 5, 2011:1503–10
Eagle, Cannon 1507
Scanning the Literature
and provides an easy tool for risk stratification of patients with
NSTE-ACS.  
Summary written by: Hitinder S. Gurm, MBBS
The Impact of Postrandomization Crossover of
Therapy in Acute Coronary Syndromes Care
Mahaffey KW, Pieper KS, Lokhnygina Y, et al., on behalf of the 
SYNERGY Investigators.
Circ Cardiovasc Qual Outcomes 2011;Feb 8:[Epub ahead of print].
Study Question: What is the implication of post-randomiza-
tion crossover of care in patients with acute coronary
syndrome (ACS)? 
Methods: The authors assessed the outcome of patients
enrolled in the SYNERGY trial who crossed over to another
therapy after randomization, and compared them to those
without crossover. The impact of crossover on the overall
outcome of the trial was assessed using inverse probability
weighting (IPW). The analysis included 9,613 (96.3%)
patients who received at least 1 dose of randomized therapy. 
Results: Post-randomization crossover occurred in 7.7% of
patients (554 enoxaparin, 186 unfractionated heparin
[UFH]). In unadjusted analysis, crossover patients had higher
rates of 30-day death/myocardial infarction (MI) (18.9% vs.
14.0%), TIMI major bleeding (16.9% vs. 7.6%), GUSTO
severe bleeding (4.5% vs. 2.3%), and transfusions (32.3% vs.
15.2%). Adjustment using the IPW technique suggested that
crossover had minimal impact on study outcome, with the
30-day death or MI rate changing from 13.9% and 14.5%
(enoxaparin vs. UFH) to 13.3% and 14.2%. 
Conclusions: Patients with post-randomization crossover had
worse outcome compared with those without crossover, but
use of appropriate adjustment suggested that crossover had
only minimal impact on overall treatment effect.
Perspective: This study highlights the significant bias that
limits any interpretation of outcome of a subgroup of
patients who cross over from one therapy to another in a
clinical trial. Data from such an analysis should be inter-
preted cautiously and should serve at best as hypothesis
generating.  
Summary written by: Hitinder S. Gurm, MBBS
Heart Failure/Transplant
Recommendations for the Use of Natriuretic
Peptides in Acute Cardiac Care: A Position
Statement From the Study Group on Biomarkers in
Cardiology of the ESC Working Group on Acute
Cardiac Care
Thygesen K, Mair J, Mueller C, et al.
Eur Heart J 2011;Feb 2:[Epub ahead of print].
Perspective: The European Society of Cardiology (ESC) out-
lined principles for the application of natriuretic peptide
levels to care for patients with heart failure. The following
are 10 points to remember: 
1: While B-type natriuretic peptide (BNP) is expressed
mostly in the atria of normal hearts, its production is upreg-
ulated in high wall stress states (e.g., heart failure and renal
failure), promoting diuresis, natriuresis, vasodilation, and
renin-angiotensin-aldosterone system (RAAS) antagonism.
2: PreproBNP is cleaved to form proBNP. This is then
cleaved into BNP and N-terminal (NT)-proBNP. Patients
with heart failure often have high concentrations of rela-
tively inactive glycosylated proBNP which cannot be
converted to active BNP. 
3: BNP is cleared via endopeptidases, clearance receptors,
and renally. NT-proBNP is cleared passively by high blood
flow organs. Renal dysfunction leads to elevation of both
peptides.
4: Natriuretic peptides are neither heart failure nor heart dis-
ease specific. 
5: Because the intrapatient natriuretic peptide’s biological
variability is 30-50%, large changes must occur within
patients for them to be deemed clinically important (>30%
change). Thus, frequent blood sampling during acute man-
agement is not recommended.
6: Natriuretic peptide levels may not be elevated despite
acute hemodynamic compromise and pulmonary congestion
in those with preserved ejection fraction, constrictive peri-
carditis, and acute mitral regurgitation.
7: Both BNP and NT-proBNP have reduced sensitivity in
severe obesity.
8: In the setting of normal renal function and body mass
index, a BNP <100 ng/L and NT-proBNP <300 ng/L
makes the diagnosis of heart failure less likely. A BNP level
>500 ng/L makes a heart failure diagnosis more likely.
9: Natriuretic peptide measurements on admission can pro-
vide risk stratification and predict short- and long-term
mortality. A BNP that reduces >30% from admission to dis-
charge is associated with improved survival.
10: Natriuretic peptide measurements can be prognostic in
the setting of several nonheart failure-related conditions
such as acute pulmonary embolism and acute coronary syn-
drome. 
Summary written by: Jennifer Ann Cowger, MD
1508 Eagle, Cannon
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Association of Candesartan vs Losartan With 
All-Cause Mortality in Patients With Heart Failure
Eklind-Cervenka M, Benson L, Dahlström U, Edner M, Rosenqvist
M, Lund LH.
JAMA 2011;305:175–182.
Study Question: What is the association of candesartan versus
losartan with all-cause mortality in patients with heart fail-
ure (HF)? 
Methods: The authors used the Swedish Heart Failure
Registry of 30,254 patients registered from 62 hospitals and
60 outpatient clinics. A total of 5,139 patients (mean age,
74 years; 39% women) were treated with candesartan (n =
2,639) or losartan (n = 2,500). They analyzed survival (as of
December 14, 2009) by angiotensin-receptor blocker (ARB)
agent using the Kaplan-Meier method, and predictors of
survival were determined by univariate and multivariate pro-
portional hazard regression models. The main outcome
measures were all-cause mortality at 1 and 5 years.
Results: The investigators found that 1-year survival was
90% for patients receiving candesartan and 83% for patients
receiving losartan, and 5-year survival was 61% and 44%,
respectively (log-rank p < 0.001). The multivariate analysis
with adjustment for propensity scores showed that the haz-
ard ratio for mortality for losartan compared with
candesartan was 1.43. These results persisted in stratified
analyses.
Conclusions: In this registry of patients with HF, the use of
candesartan compared with losartan was associated with a
lower mortality risk. 
Perspective: This study suggests that the so-called ‘class effect’
has limitations. Not all statins are the same; cerivastatin
(Baycol) was withdrawn from the market. And not all beta-
blockers are the same; bucindolol did not have the same
benefits in HF, unlike other beta-blockers in the BEST
study. Randomized controlled trials are needed to determine
which ARB is ‘best-of-breed’ in the management of HF.
Summary written by: Ragavendra R. Baliga, MBBS
The Association Between Hospital Volume and
Processes, Outcomes, and Costs of Care for
Congestive Heart Failure
Joynt KE, Orav EJ, Jha AK.
Ann Intern Med 2011;154:94–102.
Study Question: Do hospitals with more experience in caring
for patients with congestive heart failure (CHF) provide
better, more efficient care? 
Methods: This was a retrospective cohort study of 4,095 US
hospitals with primary discharge diagnosis of CHF in
Medicare fee-for-service patients (1,029,497 discharges).
The investigators examined Hospital Quality Alliance CHF
process measures; 30-day, risk-adjusted mortality rates; 30-
day, risk-adjusted readmission rates; and costs per discharge.
The investigators also used National Medicare claims data
from 2006 to 2007 to determine the relationship between
hospital case volume (low volume = 25-200 discharges,
medium volume = 201-400 discharges, and high volume =
>400 discharges) and quality, outcomes, and costs for
patients with CHF ages ≥65 years.
Results: Hospitals in the low-volume group had lower per-
formance on the process measures (80.2%) than did
medium-volume (87.0%) or high-volume (89.1%) hospitals
(p < 0.001). In the low-volume group, being admitted to a
hospital with a higher case volume was associated with
lower mortality, lower readmission, and higher costs.
Similar, though smaller, relationships were found between
case volume and both mortality and costs in the medium-
and high-volume hospital groups.
Conclusions: Experience with managing CHF is associated
with higher quality of care and better outcomes for patients,
but a higher cost. Understanding which practices employed by
high-volume institutions account for these advantages can
help improve quality of care and clinical outcomes for all
patients with CHF. 
Perspective: This study has an important message that sug-
gests high-volume hospitals with probably better resources
for management of HF and more efficient utilization of
resources are associated with cost savings and improved mor-
tality. Prospective data are now needed to support these
important findings so that hospitals can make thoughtful
provisions to improve the management of HF. However,
before designing a new study, keep in mind that current HF
performance measures may have little relationship to patient
mortality and combined mortality/rehospitalization in the
first 60-90 days after discharge.
Summary written by: Ragavendra R. Baliga, MBBS
Noninvasive Cardiology
Efficacy of Quantified Home-Based Exercise and
Supervised Exercise in Patients With Intermittent
Claudication: A Randomized Controlled Trial
Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM.
Circulation 2011;123:491–498.
Study Question: Is a home-based exercise program for claudica-
tion as effective as a supervised exercise program in improving
JACC,  Vol. 57, No. 14, 2011
April 5, 2011:1503–10
Eagle, Cannon 1509
Scanning the Literature
claudication measures, exercise performance, and daily ambu-
latory activity?   
Methods: This was a prospective, controlled clinical trial in
which 119 patient claudicants were randomized to either
home-based exercise (29), supervised exercise (33), or usual-
care control (30). All wore step activity monitors during
exercise sessions (3 days/week) and both active arms con-
sisted of intermittent walking to near maximal claudication
pain for 12 weeks. Primary outcome measures included clau-
dication onset time (COT) and peak walking time (PWT)
on treadmill exercise tests. Secondary outcomes were daily
ambulatory cadences.
Results: Patient demographics and dropout rates were similar
between all groups. Adherence to the home-based exercise
program was similar to that of supervised exercise (p =
0.712) and both exceeded 80%. There were no changes in
COT, PWT, or ambulatory cadence in the control group.
Both exercise programs increased COT (p < 0.001) and
PWT (p < 0.01), but only the home-based program resulted
in increased ambulatory cadences (p < 0.01). There was a
significant increase in ambulatory cadence in the home-
based compared to the supervised exercise group (p < 0.05). 
Conclusions: Home-based exercise is efficacious in improving
claudication measures, exercise performance, and daily ambu-
latory activity in patients with intermittent claudication.
Compared to a supervised exercise program, home-based exer-
cise results in increased daily ambulatory cadence, and may
result in superior community-based ambulation. 
Perspective: A structured program of supervised ambulation has
been repeatedly shown in trials to improve claudication symp-
toms. Unfortunately, third-party payers have been reluctant to
pay for supervised exercise programs for claudicants. My per-
sonal experience with instructing a claudicant to exercise is
that this only occasionally results in success. Thus, it is heart-
ening to see that a home-based exercise program for
claudicants may result in equivalent, if not greater, benefit to
patients as a supervised exercise program.
Summary written by: John E. Rectenwald, MD
Appropriate Use Criteria for Stress Single-Photon
Emission Computed Tomography Sestamibi
Studies: A Quality Improvement Project
Gibbons RJ, Askew JW, Hodge D, Kaping B, Carryer DJ, Miller T.
Circulation 2011;123:499–503.
Study Question: What is the impact of an internal quality
improvement project (QIP) on compliance with appropriate
use criteria (AUC) for single-photon emission computed
tomographic sestamibi (SPECT)? 
Methods: This is the third in a series of studies from a single
center evaluating the adherence to AUC for SPECT. The
first study in May 2005, revealed that four indications
accounted for 88% of inappropriate studies. These were
indication 10, asymptomatic low-risk; indication 32, inter-
mediate-risk surgery good exercise capacity preoperative;
indication 1, symptomatic low test probability with inter-
pretable electrocardiogram; and indication 31, preoperative
low-risk surgery. Approximately 48% of inappropriate stud-
ies were attributable to asymptomatic low-risk patients. A
follow-up study in 2006 revealed that the prevalence of
inappropriate studies decreased from 14.7 to 7.0. Following
this, the authors developed an educational “intervention”
including presentations at grand rounds, dissemination of
the study summary outlining inappropriate indications, etc.
The current study used identical methodology to character-
ize 273 SPECT patients studied between March 16 and
April 4, 2008.
Results: The patients in the 2008 study were similar with
respect to demographics and clinical characteristics to the
patients studied in 2005 and 2006. The most common
indication for SPECT was testing following revasculariza-
tion (32%), evaluation of symptoms (26%), and follow-up
after prior SPECT (22%) and screening in asymptomatic
patients (14%). This distribution is similar to that in the
previous studies. The rate of inappropriate SPECT studies
was 14.4% in May 2005 and had declined to 7.0% in
October 2006 (p = 0.004). For the March 2008 cohort, the
prevalence of inappropriate studies rose to 11.7% (p = 0.34
compared to 2005; p = 0.06 compared to October 2006).
Conclusions: A quality improvement project directed at physi-
cian education and feedback did not reduce the rate of
inappropriate SPECT studies. 
Perspective: The authors discuss a variety of reasons why this
educational intervention failed, none of which account for a
substantial increase in inappropriate studies after the 2006
cohort. AUC exist and are in evolution for virtually all imag-
ing modalities, and the current iteration of each appears well
thought out and reasonable from the perspective of clinical
care. The fact that a well-organized, well-attended, educa-
tional program directed at increasing compliance with AUC
failed to do so in a fairly closed institution with tremendous
resources does not bode well for similar efforts in less struc-
tured environments.
Summary written by: William F. Armstrong, MD
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